TPO2 Antibody

What is TPX2 and what cellular functions does it regulate?

TPX2 (Targeting Protein for Xklp2) functions as a critical spindle assembly factor required for normal mitotic spindle assembly. It plays essential roles in microtubule nucleation dependent on chromatin and/or kinetochores during mitosis. TPX2 mediates Aurora kinase A (AURKA) localization to spindle microtubules and activates AURKA by promoting its autophosphorylation at Thr-288 while protecting this residue against dephosphorylation. At the onset of mitosis, TPX2 is released from importin-alpha through GOLGA2 interaction, allowing it to activate AURKA kinase and stimulate local microtubule nucleation .

What are the key differences between TPO-1 and TPO-2 isoforms?

Thyroid peroxidase (TPO) exists in at least two isoforms. TPO-1 is the full-length protein consisting of 933 amino acids, while TPO-2 is an alternatively spliced variant that lacks exon 10 and is 57 residues shorter. Both forms appear on gel electrophoresis as a closely migrating double band of approximately 105 kDa (larger form) and 100 kDa (smaller form). Research has confirmed that both bands contain TPO-1, with the difference likely resulting from post-translational modifications. TPO-2 represents less than 10% of total TPO expressed in thyroid tissue, suggesting it has a specific role in thyroid function that requires further investigation .

How do antibodies against specific extracellular domains function in research applications?

Antibodies targeting specific extracellular domains of proteins can provide powerful tools for both research and potential therapeutic applications. These antibodies can be designed to block specific protein-protein interactions or signaling pathways. For example, antibodies against the extracellular domain of TLR2 have been shown to inhibit TLR2 agonist-driven inflammatory responses by blocking the receptor's ability to recognize pathogen-associated molecular patterns (PAMPs). This approach enables researchers to study the role of specific domains in protein function and potentially develop therapeutic strategies targeting these domains .

What validation techniques should be employed when using TPX2 antibodies in cancer research?

When using TPX2 antibodies in cancer research, comprehensive validation should include:

• Western blot analysis: Confirming specific binding at the expected molecular weight (~100 kDa) in cancer cell lines known to express TPX2.

• Immunohistochemistry controls: Using positive controls (tissues with known TPX2 expression like proliferative cells in colon, breast, and lung cancers) and negative controls (secondary antibody only).

• Subcellular localization verification: Using immunofluorescence to confirm TPX2's expected localization pattern during different cell cycle phases.

• Flow cytometry validation: Testing on multiple cell lines with different expression levels to establish sensitivity and specificity.

• Knockdown/knockout verification: Demonstrating reduced antibody signal in cells with TPX2 knockdown or knockout.

Research has validated TPX2 antibody staining in proliferative cells of human colon, breast, and lung cancer tissues, making it a valuable tool for studying its role in cancer progression .

How can researchers design antibodies with custom specificity profiles for closely related epitopes?

Designing antibodies with custom specificity profiles involves:

• High-throughput sequencing approach: Combining phage display selection with computational analysis to identify binding modes associated with particular ligands.

• Biophysics-informed modeling: Using energy functions to predict binding specificity of antibody sequences.

• Optimization strategy: For specific binding to a single target, researchers should minimize the energy function associated with the desired ligand while maximizing those associated with undesired ligands.

• Cross-specificity design: For antibodies that need to bind to multiple targets, jointly minimizing the energy functions associated with all desired ligands.

• Experimental validation: Testing predicted antibody sequences through binding assays to confirm desired specificity profiles.

This approach allows researchers to develop antibodies that can discriminate between very similar epitopes, even when these epitopes cannot be experimentally dissociated from others present in the selection process .

What are the recommended protocols for detecting low-abundance TPO-2 isoform in thyroid tissue samples?

To detect the low-abundance TPO-2 isoform (representing <10% of total TPO) in thyroid tissue:

• Immunodepletion strategy: Use anti-exon 10 peptide antibodies to selectively deplete TPO-1 from the sample, enriching for TPO-2.

• Comparative antibody analysis: Employ both anti-exon 10 specific antibodies (which only bind TPO-1) and antibodies recognizing both isoforms, then compare binding patterns.

• SDS-PAGE with western blotting: Perform high-resolution gel electrophoresis under reducing conditions to separate the closely migrating bands.

• Electroelution purification: Isolate specific TPO bands from purified thyroid microsomes for further analysis.

• Quantitative comparison: Assess relative binding of anti-exon 10 antibodies versus pan-TPO antibodies to quantify TPO-2 presence.

This approach has successfully demonstrated that TPO-2 constitutes approximately 5-10% of total TPO in Graves' thyroid tissue .

How should researchers address protein degradation issues when working with TPX2 antibodies in western blotting?

To minimize TPX2 protein degradation in western blotting:

• Sample preparation timing: Prepare lysates freshly and use them immediately to minimize protein degradation.

• Protease inhibitor cocktail: Include a comprehensive protease inhibitor cocktail in lysis buffers.

• Buffer optimization: Use 5% non-fat dry milk in TBST as blocking and diluting buffer as validated for TPX2 antibodies.

• Sample handling: Maintain samples at cold temperatures during preparation and avoid repeated freeze-thaw cycles.

• Expected banding pattern: Be aware that the molecular weight observed should be consistent with published literature (references PMID:25239289, 16489064).

Following these recommendations will help ensure detection of intact TPX2 protein and avoid artifacts from degradation products .

What controls are essential when investigating TPO autoantibodies in autoimmune thyroid disease research?

Essential controls for TPO autoantibody research include:

• Isoform-specific controls: Use antibodies specifically recognizing exon 10 (present only in TPO-1) alongside antibodies recognizing both TPO isoforms.

• Epitope mapping controls: Include recombinant human Fab fragments and mouse monoclonal antibodies that define the TPO immunodominant region.

• Disease specificity controls: Compare samples from Graves' disease patients with other autoimmune thyroid conditions and healthy controls.

• Post-translational modification assessment: Account for differences in glycosylation patterns that affect antibody recognition.

• Cross-reactivity testing: Ensure antibodies do not cross-react with other peroxidases or structurally similar proteins.

These controls help establish the epitopic relationships between different antibodies and accurately characterize the immunodominant regions on TPO recognized in autoimmune conditions .

What are the optimal fixation and permeabilization conditions for TPX2 detection in immunofluorescence studies?

For optimal TPX2 detection in immunofluorescence:

• Fixation protocol: Use 4% paraformaldehyde fixation which has been validated for TPX2 antibody staining.

• Permeabilization conditions: 0.1% Triton X-100 is recommended for adequate permeabilization while preserving cellular structures.

• Antibody dilution: A 1:100 dilution of primary TPX2 antibody has been validated for immunofluorescence applications.

• Secondary antibody selection: Use fluorophore-conjugated secondary antibodies such as Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488).

• Cellular structures visualization: Consider counterstaining to visualize spindle microtubules and DNA to confirm proper TPX2 localization during different cell cycle phases.

These conditions have been validated for successful TPX2 detection in various cell lines including HEK-293 cells .

How does TPX2 expression correlate with cellular proliferation markers in different cancer types?

TPX2 expression shows strong correlation with proliferation in multiple cancer types:

• Colon cancer: TPX2 antibody staining demonstrates positive labeling in proliferative cells of human colon cancer tissue, consistent with its role in mitotic spindle assembly.

• Breast cancer: Strong TPX2 expression has been observed in proliferative cells of human breast cancer tissue, as demonstrated by immunohistochemical analysis.

• Lung cancer: Proliferative cells in lung cancer tissue show significant TPX2 expression, confirming its value as a potential proliferation marker.

• Expression pattern: TPX2 shows a cell cycle-dependent expression pattern with highest levels during G2/M phases.

• Co-localization studies: TPX2 co-localizes with other mitotic markers and Aurora kinase A at the mitotic spindle during cell division.

These findings suggest TPX2 antibodies can serve as valuable tools for assessing proliferation status in cancer tissues and potentially guide therapeutic strategies targeting cell division .

What are the implications of TPO-2 expression levels in autoimmune thyroid disease pathogenesis?

The implications of TPO-2 expression in autoimmune thyroid disease include:

• Differential autoantibody recognition: The absence of exon 10 in TPO-2 may create unique epitopes recognized by distinct autoantibody populations.

• Tissue-specific expression patterns: The proportion of TPO-2 versus TPO-1 varies between different Graves' thyroid microsome preparations, suggesting possible disease-specific regulation.

• Functional considerations: Despite representing <10% of total TPO in thyroid tissue, the conservation of TPO-2 suggests it has a specific biological function.

• Diagnostic implications: The presence of TPO-2-specific autoantibodies might serve as more specific biomarkers for particular autoimmune thyroid conditions.

• Therapeutic targeting: Understanding TPO isoform-specific immune responses could enable more targeted immunotherapeutic approaches.

Research has confirmed that TPO-2 is expressed at low levels in Graves' thyroid tissue, but its precise role in disease pathogenesis requires further investigation .

How can computational modeling advance the design of antibodies with enhanced specificity for closely related epitopes?

Computational modeling enhances antibody specificity design through:

• Mode identification: Identifying distinct binding modes associated with specific ligands, even when these ligands are chemically very similar.

• Energy function optimization: Using mathematical optimization of energy functions to design antibodies with predefined binding profiles.

• Cross-reactivity prediction: Predicting potential cross-reactivity with similar epitopes before experimental validation.

• Library design enhancement: Informing the design of focused libraries for directed evolution experiments.

• Bias mitigation: Computational approaches can help mitigate experimental artifacts and biases inherent in selection experiments.

This biophysics-informed modeling approach, when combined with extensive selection experiments, allows researchers to create antibodies with either highly specific binding to particular target ligands or controlled cross-specificity for multiple targets, offering significant advantages over traditional selection methods alone .